IL91649A - A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines - Google Patents

A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines

Info

Publication number
IL91649A
IL91649A IL9164989A IL9164989A IL91649A IL 91649 A IL91649 A IL 91649A IL 9164989 A IL9164989 A IL 9164989A IL 9164989 A IL9164989 A IL 9164989A IL 91649 A IL91649 A IL 91649A
Authority
IL
Israel
Prior art keywords
antibody
fibrin
tpa
prourokinase
hybridoma
Prior art date
Application number
IL9164989A
Other languages
English (en)
Hebrew (he)
Other versions
IL91649A0 (en
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of IL91649A0 publication Critical patent/IL91649A0/xx
Publication of IL91649A publication Critical patent/IL91649A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL9164989A 1988-09-27 1989-09-15 A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines IL91649A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
IL91649A0 IL91649A0 (en) 1990-04-29
IL91649A true IL91649A (en) 1994-10-21

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9164989A IL91649A (en) 1988-09-27 1989-09-15 A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines

Country Status (15)

Country Link
US (1) US5506135A (da)
EP (1) EP0363712B1 (da)
JP (1) JP3177776B2 (da)
KR (1) KR900004351A (da)
CN (1) CN1041783A (da)
AR (1) AR242832A1 (da)
AT (1) ATE140930T1 (da)
AU (1) AU628857B2 (da)
DE (1) DE68926899T2 (da)
DK (1) DK474189A (da)
FI (1) FI894551A (da)
HU (1) HUT55445A (da)
IL (1) IL91649A (da)
NO (1) NO893818L (da)
PT (1) PT91808B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (da) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
JP6473418B2 (ja) * 2013-10-10 2019-02-20 幸成 加藤 抗ポドプラニン抗体
CN110582514B (zh) * 2017-05-02 2024-03-01 国立研究开发法人国立癌症研究中心 纤溶酶可切割的抗不溶性纤维蛋白的抗体与药物的偶联物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies

Also Published As

Publication number Publication date
AU628857B2 (en) 1992-09-24
DE68926899D1 (de) 1996-09-05
DE68926899T2 (de) 1997-01-02
FI894551A (fi) 1990-03-28
JP3177776B2 (ja) 2001-06-18
PT91808A (pt) 1990-03-30
KR900004351A (ko) 1990-04-12
FI894551A0 (fi) 1989-09-26
HUT55445A (en) 1991-05-28
EP0363712A2 (en) 1990-04-18
NO893818D0 (no) 1989-09-26
AR242832A1 (es) 1993-05-31
JPH03103175A (ja) 1991-04-30
ATE140930T1 (de) 1996-08-15
EP0363712B1 (en) 1996-07-31
IL91649A0 (en) 1990-04-29
PT91808B (pt) 1995-05-31
CN1041783A (zh) 1990-05-02
DK474189A (da) 1990-03-28
NO893818L (no) 1990-03-28
EP0363712A3 (en) 1990-08-16
DK474189D0 (da) 1989-09-26
AU4174789A (en) 1990-04-05
US5506135A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
EP0450479B1 (en) Bispecific monoclonal anti-bodies, their production and use
EP0419574B1 (en) Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same
KR100585473B1 (ko) 혈액 응고를 억제하기 위한 항체 및 그의 사용 방법
US20090252726A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
KR20050040844A (ko) 혈액 응고를 억제하기 위한 항체 및 이의 사용 방법
JPH05304992A (ja) ハイブリッド・モノクローナル抗体および抗体含有薬剤
EP0241907A2 (en) Heterobifunctional antibodies and method of use
EP0363712B1 (en) Hybrid monoclonal antibodies, their production and use
US5620688A (en) Methods of inhibiting the activation of Factor XIII
Kurokawa et al. Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator
US5453269A (en) Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
Hayzer et al. Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents
US7247453B1 (en) Calcium binding recombinant antibody against protein C
KR930002834B1 (ko) 항유로키나제 모노클론 항체 함유 면역흡착제 및 이를 사용하는 유로키나제 정제방법
EP0513778A2 (en) Hybrid monoclonal antibodies and compositions containing them
EP0491351A2 (en) Chimeric antibodies and their use
JPH02142494A (ja) 抗ウロキナーゼモノクローナル抗体
JPS61186399A (ja) 抗ヒトアンジオテンシン変換酵素抗体
JPH04218389A (ja) 二重特異性抗体および抗体含有薬剤
Charpie Monoclonal antibodies specific for single-chain urokinase: applications in targeted thrombolysis
CA2056118A1 (en) Monoclonal antibodies which bind mannose binding protein
JPH0575394B2 (da)
JPH0995500A (ja) モノクローナル抗体および血栓溶解促進剤

Legal Events

Date Code Title Description
RH Patent void